Raymond James Financial raised Nvidia's target price to $120.
NVIDIA Analyst Ratings
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Intuitive Surgical Analyst Ratings
Cognex Analyst Ratings
Evercore ISI Adjusts Price Target on Intuitive Surgical to $425 From $385, Maintains In-line Rating
After in-depth research on the Taiwan chip industry chain, Morgan Stanley significantly raised Nvidia's target price to $144.
NVIDIA Analyst Ratings
Morgan Stanley Adjusts Price Target on NVIDIA to $144 From $116, Maintains Overweight Rating
DBS: Raised nvidia's target price to $144.
Truist Adjusts Price Target on NVIDIA to $140 From $128.80, Maintains Buy Rating
Cantor Fitzgerald Raises Price Target on NVIDIA to $175 From $140, Maintains Overweight Rating
Citi is bullish on the prospects of enterprise AI reasoning and has raised the target price of Nvidia (NVDA.US) to $150.
NVIDIA Analyst Ratings
Loop Capital Maintains Hold on Dynatrace, Lowers Price Target to $45
Dynatrace Analyst Ratings
Guggenheim Reiterates Buy on Dynatrace, Maintains $60 Price Target
Jefferies Maintains Buy on NVIDIA, Raises Price Target to $150
Nvidia's Price Target Raised at Jefferies on More Upside With Beats Accelerating
Jefferies Financial: Raises Nvidia's target price to $150, and increases revenue and EPS forecasts for the 2025-2026 fiscal years.